TrialNature communications2023

Neoadjuvant sintilimab in combination with concurrent chemoradiotherapy for locally advanced gastric or gastroesophageal junction adenocarcinoma: a single-arm phase 2 trial.

Jia Wei et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.